Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 23,109 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard Clear all
Completed Phase 4 Interventional Results available

Pre vs Post Block in Total Knee Arthroplasty (TKA)

NCT05974501
View directory record Official record
Conditions
Knee Osteoarthritis, Arthroplasty Complications, Postoperative Pain
Interventions
Dexamethasone, Acetaminophen, Lyrica, Celebrex, Meloxicam, Oxycodone, Ropivacaine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 17, 2026, 7:41 PM EDT
Completed Phase 1Phase 2 Interventional

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

NCT04660812
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
AB680, Etrumadenant, Zimberelimab, Bevacizumab, m-FOLFOX-6 regimen, Regorafenib
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
17
States / cities
Tucson, Arizona • Duarte, California • Santa Monica, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 17, 2026, 7:41 PM EDT
Terminated Not applicable Interventional

7T MRI Scan for the Early Detection of Melanoma Brain Metastases

NCT04941430
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Magnetic Resonance Imaging using 7 Tesla MRI
Diagnostic Test
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 17, 2026, 7:41 PM EDT
Completed No phase listed Observational

Study of Tumor Samples From Patients With Lung Cancer

NCT00900328
View directory record Official record
Conditions
Lung Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 17, 2026, 7:41 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

REFLECTION: A Clinical Practice Learning Program for Galleri®

NCT05205967
View directory record Official record
Conditions
Early Detection of Cancer, Cancer
Interventions
MCED, SOC
Other
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
22 Years and older
Enrollment
14,633 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
16
States / cities
Scottsdale, Arizona • Burbank, California • Fullerton, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 17, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00654836
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, Carboplatin, ABI-007
Biological · Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
6
States / cities
Downers Grove, Illinois • Geneva, Illinois • Maywood, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 17, 2026, 7:41 PM EDT
Completed Not applicable Interventional Results available

Secondary HIV Prevention and Adherence Among HIV-infected Drug Users

NCT01741311
View directory record Official record
Conditions
Risk Behavior, Medication Adherence, HIV
Interventions
3H+ (Holistic Health for HIV), HHRP+ (Holistic Health Recovery Program)
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 17, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics

NCT01139294
View directory record Official record
Conditions
Dehydration, Cardiac Output, Pediatrics
Interventions
Hylenex
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
2 Months to 3 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 17, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

NCT02504294
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
Epoetin Hospira Arm, Standard of Care Arm, IV Iron
Biological · Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
42
States / cities
Chula Vista, California • Poway, California • Rancho Bernardo, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 17, 2026, 7:41 PM EDT
Recruiting Phase 3 Interventional

IS-001 Injection in Patients Undergoing Robotic-Assisted Colorectal Surgery

NCT07346066
View directory record Official record
Conditions
Ureter Injury
Interventions
filricianine
Drug
Lead sponsor
Intuitive Surgical
Industry
Eligibility
16 Years to 75 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Newport Beach, California • New Haven, Connecticut • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 17, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Results available

Liposomal Bupivacaine With or Without Hydromorphone for the Improvement of Pain Control After Laparotomy in Patients With Gynecological Malignancies

NCT04258631
View directory record Official record
Conditions
Malignant Female Reproductive System Neoplasm
Interventions
Hydromorphone, Laparotomy, Liposomal Bupivacaine, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 17, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

NCT02799602
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
58
States / cities
Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 17, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI

NCT02833753
View directory record Official record
Conditions
Colorectal Cancer, Appendix Cancer, Peritoneal Carcinomatosis
Interventions
Oxaliplatin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 17, 2026, 7:41 PM EDT
Active, not recruiting Phase 4 Interventional

Exparel Injection for Postoperative Orbital Pain

NCT02381353
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Bupivacaine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 17, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes

NCT00677053
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
TAK-442, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
30 Years to 80 Years
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 17, 2026, 7:41 PM EDT
Recruiting Phase 4 Interventional

Efficacy Bioinductive Implant for Tennis Elbow (Lateral Epicondylitis)

NCT03718637
View directory record Official record
Conditions
Tennis Elbow, Lateral Epicondylitis
Interventions
Smith & Nephew Bioinductive Implant, Lateral Epicondylectomy, Ultrasound Imaging
Biological · Procedure · Radiation
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 17, 2026, 7:41 PM EDT
Recruiting Phase 1 Interventional

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

NCT07377045
View directory record Official record
Conditions
Pancreatic Adenocarcinoma Metastatic
Interventions
OMTX705, Nab-paclitaxel + Gemcitabine, Tislelizumab (i.v. 200mg)
Drug
Lead sponsor
Oncomatryx Biopharma S.L.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 7:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Robotic OCT for ER Anterior Eye Exams

NCT06566339
View directory record Official record
Conditions
Develop and Test Robotically Assisted Imaging System for the Front of the Eye
Interventions
Robotically Aligned Eye Imaging System
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 17, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Computer Aided Detection, Tandem Colonoscopy Study

NCT04074577
View directory record Official record
Conditions
Colonic Diseases
Interventions
Standard technique First, combination technique First
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
22 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 17, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Physical Activity and Social-media Support

NCT04744077
View directory record Official record
Conditions
Trust
Interventions
Influencer Instagram account, Research study Instagram account
Behavioral
Lead sponsor
California State Polytechnic University, Pomona
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 17, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

NCT02456857
View directory record Official record
Conditions
Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Bevacizumab, Everolimus, Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 17, 2026, 7:41 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage

NCT05853601
View directory record Official record
Conditions
Acute Kidney Injury, HIE
Interventions
Single Dose Theophylline, Repeat Dose Theophylline
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Hour to 18 Hours
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 17, 2026, 7:41 PM EDT
Completed Not applicable Interventional Results available

Supplement to Hospital to Home Outcomes

NCT03224130
View directory record Official record
Conditions
Hospitalized Patients
Interventions
Nurse Phone Call, Standard of Care
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 18 Years
Enrollment
966 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 17, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 17, 2026, 7:41 PM EDT